Siteman Cancer Center-Washington University

St Louis, Missouri 63130

3 studies enrolling now · 8 studies all time

What they study most

Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Breast Cancer, Hepatosplenic T-cell Lymphoma, KRAS Altered Advanced or Metastatic Solid Tumors, Metastatic Breast Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Non-Small Cell Lung, Non-small Cell Lung Carcinoma, Peripheral T-cell Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Relapsed/Refractory Acute Leukemia

Studies at this site

• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors — Recruiting now
• Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment — Recruiting now
• A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma — Recruiting now
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer — Running, not enrolling
• Expanded Access Program for Revumenib — NO_LONGER_AVAILABLE
• Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma — Completed
• An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Status unconfirmed
• Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC — Completed